Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients

  • Pan, Jin-Bing (Department of Respiratory Medicine, Henan Provincial People's Hospital) ;
  • Hou, Yu-Hong (Department of Emergency, First Affiliated Hospital of Zhengzhou University) ;
  • Zhang, Guo-Jun (Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Mutations affecting the epidermal growth factor receptor (EGFR) are good predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer. Serum carcinoembryonic antigen (CEA) levels are also regarded as predictive for the efficacy of EGFR-TKI and EGFR gene mutations. This study analyzed the association between EGFR gene mutations and clinical features, including serum tumor marker levels in lung adenocarcinomas patients. Patients and Methods: A total of 70 lung adenocarcinoma patients with complete clinical data and pathological specimens were investigated. EGFR gene mutations at exons 19 and 21 were assessed. Serum tumor markers were detected by protein chip-chemiluminescence at the corresponding time, and correlations were analyzed. Results: Mutations of the EGFR gene were detected in 27 of the 70 patients and the serum CEA and CA242 concentrations were found to be significantly associated with the incidence of EGFR gene mutations (P<0.05). The AUCs for CEA and CA242 were 0.724 (95% CI: 0.598~0.850, P<0.05) and 0.769 (95% CI: 0.523~0.800, P<0.05) respectively. Conclusions: Serum CEA and CA242 levels are associated with mutations of the EGFR gene in patients with lung adenocarcinomas.

Keywords

References

  1. Addison CL, Ding K, Zhao H, et al (2010). Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol, 28, 5247-56. https://doi.org/10.1200/JCO.2010.31.0805
  2. Bedi A, Pasricha PJ, Akhtar AJ, et al (1995). Inhibition of apoptosis during development of colorectal cancer. Cancer Res, 55, 1811-6.
  3. Bronte G, Rizzo S, La Paglia L, et al (2010). Driver mutations and differential sensitivity to targeted therapies, a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev, 3, S21-9.
  4. Cappuzzo F, Magrini E, Ceresoli GL, et al (2004). Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 96, 1133-41. https://doi.org/10.1093/jnci/djh217
  5. Chen F, Luo X, Zhang J, et al (2010). Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Med Oncol, 27, 950-7. https://doi.org/10.1007/s12032-009-9315-8
  6. Costa DB, Kobayashi S, Tenen DG, et al (2007). Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 58, 95-103. https://doi.org/10.1016/j.lungcan.2007.05.017
  7. Dong QG, Huang JS, Huang C, et al (2005). The progress at target therapy in lung cancer and EGFR gene mutation profile in China. (in Chinese). Tumors, 25, 625-8.
  8. Dong QG, Huang JS, Yang LM, et al (2006). Epidermal growth factor receptor gene mutations in Chinese patients with adenocarcinoma of the lung. (in Chinese). Tumor 26, 271-5.
  9. Duxbury MS, Ito H, Zinner MJ, et al (2004). CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene, 23, 465-73. https://doi.org/10.1038/sj.onc.1207036
  10. Han C, Zou H, Ma J, et al (2010). Comparison of EGFR and KRAS statusbetween primary non-small cell lung cancer and corresponding metastases, a systematic review and meta-analysis. (in Chinese). Zhongguo Fei Ai Za Zhi, 13, 882-91.
  11. Han R, Zhong W, Zhao J, et al (2011). Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma (in Chinese). Zhongguo Fei Ai Za Zhi, 14, 127-31.
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  14. Green MR (2004). Targeting targeted therapy. N Engl J Med, 350, 2191-3. https://doi.org/10.1056/NEJMe048101
  15. Jiang H (2009). Overview of gefitinib in non-smallcell lung cancer, an Asian perspective. Jpn J Clin Oncol, 39, 137-50.
  16. Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST), a randomised phase III trial. Lancet, 372, 1809-18. https://doi.org/10.1016/S0140-6736(08)61758-4
  17. Kim TJ, Choi JJ, Kim WY, et al (2008). Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci, 99, 31-8.
  18. Kosaka T, Yatabe Y, Endoh H, et al (2004). Mutations of the epidermal growth factor receptor gene in lung cancer, biological and clinical implications. Cancer Res, 64, 8919-23. https://doi.org/10.1158/0008-5472.CAN-04-2818
  19. Lamerz R (1999). Role of tumour markers, cytogenetics. Ann Oncol, 4, 145-9.
  20. Massarelli E, Andre F, Liu DD, et al (2003). A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer, 39, 55-61. https://doi.org/10.1016/S0169-5002(02)00308-2
  21. Miller VA, Kris MG, Shah N, et al (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9. https://doi.org/10.1200/JCO.2004.08.158
  22. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. https://doi.org/10.1056/NEJMoa0810699
  23. Mountain CF (1997). Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-7. https://doi.org/10.1378/chest.111.6.1710
  24. Mu XL, LI LY, HE QY (2006). The diversity of epidermal growth factor receptor tyrosine kinase domain mutations and clinical features. (in Chinese). Tumor, 26, 956-9.
  25. Okamoto T, Nakamura T, Ikeda J, et al (2005). Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer, 41, 1286-90. https://doi.org/10.1016/j.ejca.2005.03.011
  26. Ou G, Hedberg M, Horstedt P, et al (2009). Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am J Gastroenterol, 104, 3058-67. https://doi.org/10.1038/ajg.2009.524
  27. Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer, correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. https://doi.org/10.1126/science.1099314
  28. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55,74-108. https://doi.org/10.3322/canjclin.55.2.74
  29. Park K, Goto K (2006). A review of the benefit-risk profile ofgefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin, 22, 561-73. https://doi.org/10.1185/030079906X89847
  30. Pfister DG, Johnson DH, Azzoli CG, et al (2004). American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline, update 2003. J Clin Oncol, 22, 330-53.
  31. Schiller JH, Harrington D, Belani CP, et al (2002). Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
  33. Shoji F, Yoshino I, Yano T, et al (2007). Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 110, 2793-8. https://doi.org/10.1002/cncr.23101
  34. Sordella R, Bell DW, Haber DA, et al (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305, 1163-7. https://doi.org/10.1126/science.1101637
  35. Tsuchiya A, Koizumi M, Ohtani H (2009). World Health Organization Classification (2004)-based re-evaluation of 95 nonfunctioning "malignant" pancreatic endocrine tumors reported in Japan. Surg Today, 39, 500-9. https://doi.org/10.1007/s00595-008-3923-3
  36. Tufman A, Huber RM (2010). Biological markers in lung cancer, A clinician's perspective. Cancer Biomark, 6, 123-35.
  37. Yang SH, Mechanic LE, Yang P, et al (2005). Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 11, 2106-10. https://doi.org/10.1158/1078-0432.CCR-04-1853
  38. Yang X, Wang D, Li Z, et al (2007). Clinicalsignificance of multiple tumor marker protein chip in monitoring the recurrence, progression and metastasis of lung cancer. (in Chinese). Zhongguo Fei Ai Za Zhi, 10, 296-300.
  39. Yin GH, Liu Wei, Wu Yong (2009). Epidermal growth factor receptor gene mutations in Chinese patients with primary lung adenocarcinoma. (in Chinese). Chin J Gerontol, 29, 443-5.

Cited by

  1. Does Sunlight Exposure Improve Survival in Patients with Non-small Cell Lung Cancer? vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6301
  2. Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4369
  3. Therapeutic Effects and Adverse Drug Reactions are Affected by Icotinib Exposure and CYP2C19 and EGFR Genotypes in Chinese Non-Small Cell Lung Cancer Patients vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7195
  4. Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4759
  5. Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer vol.39, pp.5, 2017, https://doi.org/10.1177/1010428317705340